Tomorrow Is Not Likely To Be Same For UroGen Pharma Ltd (URGN)

UroGen Pharma Ltd (URGN) concluded trading on Wednesday at a closing price of $4.17, with 9.68 million shares of worth about $40.37 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.73% during that period and on May 21, 2025 the price saw a loss of about -44.69%. Currently the company’s common shares owned by public are about 46.10M shares, out of which, 38.22M shares are available for trading.

Stock saw a price change of -57.75% in past 5 days and over the past one month there was a price change of -58.51%. Year-to-date (YTD), URGN shares are showing a performance of -60.85% which decreased to -68.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.46 but also hit the highest price of $20.70 during that period. The average intraday trading volume for UroGen Pharma Ltd shares is 939.90K. The stock is currently trading -57.53% below its 20-day simple moving average (SMA20), while that difference is down -59.88% for SMA50 and it goes to -64.11% lower than SMA200.

UroGen Pharma Ltd (NASDAQ: URGN) currently have 46.10M outstanding shares and institutions hold larger chunk of about 91.88% of that.

The stock has a current market capitalization of $192.27M and its 3Y-monthly beta is at 0.46. It has posted earnings per share of -$3.18 in the same period. It has Quick Ratio of 5.47. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for URGN, volatility over the week remained 19.42% while standing at 11.98% over the month.

Stock’s fiscal year EPS is expected to rise by 2.09% while it is estimated to increase by 74.76% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on April 16, 2025 offering a Sector outperform rating for the stock and assigned a target price of $23 to it. Coverage by Ladenburg Thalmann stated UroGen Pharma Ltd (URGN) stock as a Buy in their note to investors on February 19, 2025, suggesting a price target of $31 for the stock. On August 22, 2024, Guggenheim Initiated their recommendations, while on February 08, 2023, Jefferies Downgrade their ratings for the stock with a price target of $10. Stock get a Buy rating from Berenberg on April 27, 2022.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.